41 related articles for article (PubMed ID: 23612885)
1. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
2. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging.
Bronstein Y; Ng CS; Rohren E; Ross MI; Lee JE; Cormier J; Johnson VE; Hwu WJ
AJR Am J Roentgenol; 2012 Apr; 198(4):902-8. PubMed ID: 22451559
[TBL] [Abstract][Full Text] [Related]
3. The clinical role of CT/PET in oncology: an update.
Francis IR; Brown RK; Avram AM
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S68-75. PubMed ID: 16361139
[TBL] [Abstract][Full Text] [Related]
4. Impact of the COVID-19 Pandemic on Staging Oncologic PET/CT Imaging and Patient Outcome in a Public Healthcare Context: Overview and Follow Up of the First Two Years of the Pandemic.
Kohan A; Menon S; Murad V; Mirshahvalad SA; Kulanthaivelu R; Farag A; Ortega C; Metser U; Veit-Haibach P
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001619
[TBL] [Abstract][Full Text] [Related]
5. Primary metastatic melanoma of the female urethra: A case report and literature review.
Bellouki O; El Aboudi A; Mikou MA; Boualaoui I; El Sayegh H; Nouini Y
Int J Surg Case Rep; 2024 Apr; 117():109569. PubMed ID: 38513417
[TBL] [Abstract][Full Text] [Related]
6. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
Lazaga FJ; Oz OK; Adams-Huet B; Anderson J; Mathews D
Clin Nucl Med; 2013 Nov; 38(11):882-4. PubMed ID: 24096999
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience.
Subesinghe M; Marples M; Scarsbrook AF; Smith JT
Insights Imaging; 2013 Oct; 4(5):701-9. PubMed ID: 24018755
[TBL] [Abstract][Full Text] [Related]
8. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
[TBL] [Abstract][Full Text] [Related]
9. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies.
Rueth NM; Xing Y; Chiang YJ; Cromwell KD; Ross MI; Lee JE; Gershenwald JE; Royal RE; Cormier JN
Ann Surg; 2014 Jun; 259(6):1215-22. PubMed ID: 24096759
[TBL] [Abstract][Full Text] [Related]
10. Whole-Body versus Routine Skull Base to Mid-thigh
Ozdemir S; McCook B; Klassen C
J Clin Imaging Sci; 2020; 10():47. PubMed ID: 32874752
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review.
Miller R; Walker S; Shui I; Brandtmüller A; Cadwell K; Scherrer E
Melanoma Manag; 2020 Mar; 7(1):MMT39. PubMed ID: 32399177
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.
Dinnes J; Ferrante di Ruffano L; Takwoingi Y; Cheung ST; Nathan P; Matin RN; Chuchu N; Chan SA; Durack A; Bayliss SE; Gulati A; Patel L; Davenport C; Godfrey K; Subesinghe M; Traill Z; Deeks JJ; Williams HC;
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012806. PubMed ID: 31260100
[TBL] [Abstract][Full Text] [Related]
13. Role of
Malik D; Sood A; Mittal BR; Basher RK; Bhattacharya A; Singh G
World J Nucl Med; 2019; 18(2):176-182. PubMed ID: 31040750
[TBL] [Abstract][Full Text] [Related]
14. Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.
Niebling MG; Bastiaannet E; Hoekstra OS; Bonenkamp JJ; Koelemij R; Hoekstra HJ
Ann Surg Oncol; 2013 Sep; 20(9):3098-105. PubMed ID: 23612885
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
17. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
18. PET/Computed Tomography and Patient Outcomes in Melanoma.
Rohren EM
PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
[TBL] [Abstract][Full Text] [Related]
19. (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
Perng P; Marcus C; Subramaniam RM
AJR Am J Roentgenol; 2015 Aug; 205(2):259-70. PubMed ID: 26204273
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
